Acetyl Chrysin Mannich Base Derivatives for CDK1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK1 inhibitors, such as flavonoids and their derivatives, face challenges with poor solubility, high 'liver first pass effect,' and low bioavailability, leading to limited efficacy and adverse reactions in cancer treatment, necessitating the development of more effective and selective inhibitors.
Innovation Solution
The synthesis of acetyl Chrysin Mannich base derivatives, which form stable six-member ring structures through intermolecular hydrogen bonds, enhancing bioavailability and selectivity as CDK1 inhibitors, thereby regulating intracellular ROS to induce apoptosis in cancer cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If flavonoids are used as CDK1 inhibitors, then selective induction of apoptosis in cancer cells is achieved, but solubility is poor and bioavailability is low
Solution Approach 1:
The patent modifies the chemical structure of flavonoids by introducing Mannich base derivatives with specific substituents (cycloalkylamine groups), which changes the physical and chemical parameters of the molecule. This structural modification improves solubility and bioavailability while maintaining the ability to selectively induce apoptosis in cancer cells through ROS regulation.
Solution Approach 2:
The invention creates composite molecular structures by combining flavonoid cores with Mannich base derivatives. This composite approach integrates the selective apoptosis-inducing capability of flavonoids with the improved pharmacokinetic properties of Mannich base structures, achieving both high reliability and improved bioavailability.
2Reliability
If flavonoids are administered orally, then anti-cancer activity is achieved, but liver first pass effect is strong and bioavailability is very low
Solution Approach 1:
By modifying the chemical parameters of flavonoids through Mannich base derivative formation, the patent reduces the extent of liver first pass metabolism. The modified structures exhibit altered metabolic profiles that decrease hepatic metabolism intensity, thereby improving oral bioavailability while preserving anti-cancer activity.
3Reliability
If CDK4/6 inhibitors are used, then cell proliferation is inhibited, but adverse reactions are serious and drug resistance occurs
Solution Approach 1:
The patent exploits the differential ROS handling between cancer and normal cells. Cancer cells lack sufficient antioxidant enzymes (SOD, GPX, CAT), making them vulnerable to ROS-induced apoptosis. The modified flavonoids selectively induce ROS accumulation in cancer cells, converting the normally harmful ROS into a therapeutic mechanism that kills cancer cells while sparing normal cells, thus reducing adverse reactions.
4Reliability
If structure modification of flavonoids is performed, then druggability is improved, but complexity of synthesis increases
Solution Approach 1:
The patent divides the molecule into distinct functional segments: a flavonoid core responsible for selective apoptosis induction and Mannich base derivative substituents responsible for improved solubility and bioavailability. This segmentation allows independent optimization of each segment's properties and simplifies the overall synthesis strategy by using modular building blocks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The acetyl Chrysin Mannich base derivatives demonstrate improved solubility, bioavailability, and selectivity for CDK1 inhibition, effectively inducing apoptosis in cancer cells with reduced toxicity and improved pharmacokinetic properties, offering a promising approach for solid cancer treatment.
Implementation Method 1
form stable six-member ring structures through intermolecular hydrogen bonds
Implementation Method 2
regulating intracellular reactive oxygen species (ROS), thus selectively induce apoptosis
Implementation Method 3
There are different mechanisms of oxidation and reduction within normal cells and tumor cells
Data Source
AI summary
Provided is a series of acetyl Chrysin Mannich base derivatives with the structures illustrated in the following scheme: wherein R1 is acetyl and R2 is cycloalkylamine-methyl, or R2 is acetyl and R1 is cycloalkylamine-methyl. Such derivatives are cyclin-dependent protein kinases 1 (CDK1) selective inhibitors. Base on the levels of .O2− and Fe++ are higher 5-15 times in cancer cells than in normal cells, the action mechanism of such derivatives by regulating intracellular reactive oxygen species (ROS) is activating mitochondria apoptosis pathway without the death receptor pathway, thus selectively inducing apoptosis of cancer cells and protecting normal cells. Inside, CH-j has a good druggability for the selectivity of solid cancers. Moreover, CH-f has also a good druggability for the systemic cancers.